Research Blog
Breaking study data, purity verification methods, and practical import guidance for research peptide buyers.
MariTide (Maridebart Cafraglutide): Amgen's Monthly GLP-1 / GIP Antagonist
Amgen's MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in a monthly-dosed peptide-antibody conjugate, an unusual mechanism in a market dominated by dual agonists.
Petrelintide: Zealand Pharma's Long-Acting Amylin Analogue
Zealand Pharma's Petrelintide is a once-weekly long-acting amylin analogue advancing through Phase 2, joining Eloralintide and Cagrilintide in the amylin class.
VK2735 Phase 3 VANQUISH Program: Viking's Dual GIP/GLP-1 Agonist
Viking Therapeutics' VK2735 has reported up to 14.7% mean weight reduction at 13 weeks in the VENTURE Phase 2 trial, with the Phase 3 VANQUISH program now fully enrolled.
Eloralintide (LY3841136): Selective Amylin Agonist Phase 2 Data Explained
Eli Lilly's selective amylin receptor agonist Eloralintide has produced 48-week Phase 2 data positioning it as a next-generation obesity candidate, with and without Tirzepatide co-administration.
The Future of GLP-1: Quad Agonists, Oral Formulations, and Extended-Interval Analogues
GLP-1 research has moved from single agonists to dual and triple agonists in less than a decade. The next wave is already in the clinic: four target agonists, oral peptide formulations, and monthly injectables that could redefine adherence.
GHK-Cu Beyond Skin: Why a Three Amino Acid Copper Peptide Modulates Thousands of Genes
GHK-Cu is widely marketed as a cosmetic peptide, but its biological footprint is far larger. Genomic analyses have shown the tripeptide modulates the expression of more than 4000 human genes, with effects spanning tissue remodelling, nerve repair, and inflammation control.
MOTS-C Research Update: What Mitochondrial Derived Peptide Studies Show So Far
MOTS-C is a 16 amino acid peptide encoded within the mitochondrial 12S rRNA gene. Since its discovery in 2015, studies have linked it to insulin sensitivity, exercise capacity, and mitochondrial function. Here is the current evidence base.
Retatrutide Phase 3 Data: What Triple-Agonist Results Mean for GLP-1 Research
Eli Lilly's triple-agonist compound Retatrutide has produced the most significant weight reduction data of any investigational peptide to date. Here is what the Phase 3 trial data shows and why researchers are paying attention.
HPLC vs Mass Spectrometry: A Practical Guide to Peptide Purity Verification
HPLC and mass spectrometry are the two primary analytical methods for verifying peptide identity and purity. Understanding their strengths, limitations, and how to interpret their results is essential for any peptide research procurement decision.
Tirzepatide Cardiovascular Outcomes: SURMOUNT-MMO Trial Results and Implications
The SURMOUNT-MMO trial is the first dedicated cardiovascular outcomes study for Tirzepatide. Early results suggest the dual GIP/GLP-1 agonist may reduce major adverse cardiac events in patients with obesity.
Endotoxin Contamination in Research Peptides: Detection, Risks, and Supplier Accountability
Endotoxin contamination is one of the most overlooked quality issues in research peptide procurement. Even high-purity peptides can contain endotoxin levels that confound cell-based studies and in vivo research. Here is what the current evidence shows.
The Finnrick Supplier Rating System: How Independent Verification Works in Peptide Supply Chains
The Finnrick rating system provides independent supplier verification in an industry where quality claims are difficult to validate. This article explains how the rating works, what the scores mean, and how to use them when selecting a peptide supplier.
Oral Semaglutide at Higher Doses: OASIS Trial Programme and the Future of Non-Injectable Peptides
Novo Nordisk's OASIS trial programme has tested higher-dose oral Semaglutide formulations, producing body-weight reduction results approaching those of the injectable formulation. This has significant implications for oral peptide research and delivery.
Customs Seizure Risks When Importing Research Peptides: A Practical Guide
International shipments of research peptides face customs scrutiny in most jurisdictions. Understanding the regulatory landscape, documentation requirements, and common seizure triggers can significantly reduce the risk of lost shipments.
Peptide Stability and Storage: Preventing Degradation in Research Settings
Even high-purity peptides can degrade rapidly under improper storage conditions. This guide covers the major degradation pathways, optimal storage conditions, and practical considerations for maximising peptide shelf life in research environments.
Heavy Metal Contamination in Peptide Synthesis: Sources, Testing, and Safe Procurement
Heavy metal residues from synthesis catalysts and reagents are an under-reported quality concern in research peptides. This article explains where contamination originates, how it affects research, and what testing to request from suppliers.